According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

The full results from the ANCHOR-1 and ANCHOR-2 studies will be presented at an upcoming scientific conference. More on GSK's Depemokimab Development Plans Earlier this year, two phase III studies ...

Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric (≥12 years old ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

GSK's phase 3 trials ANCHOR-1 and ANCHOR-2 met co-primary endpoints for treating CRSwNP with depemokimab. Adverse event rates were similar between depemokimab and placebo in the trials.

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

Presented at ERS Congress 2024; Sept. 7-11, 20924; Vienna. Manufactured by GSK, depemokimab significantly reduces asthma exacerbations through sustained suppression of type 2 inflammation ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...